Phase 1 study investigating RG0401
Latest Information Update: 11 Nov 2025
At a glance
- Drugs RG 0401 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 Oct 2025 According to RheumaGen media release, company plans to begin this Phase I clinical trial in 2027.
- 16 Jan 2025 New trial record
- 09 Jan 2025 According to RheumaGen media release, the company is currently conducting RG0401 IND-enabling studies and plans to begin the Phase I clinical trial in 2026.